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Background: Polymorphisms of genes encoding the Fcy receptors (Fc fragment of IgG receptor 2A (FCGR2A) and
3A (FCGR3A)), which influence their affinity for the Fc fragment, have been linked to the pharmacodynamics of
monoclonal antibodies. Most studies have been limited by small samples sizes and have reported inconsistent
associations between the FCGR2A and the FCGR3A polymorphisms and clinical outcome in metastatic colorectal
cancer (mCRC) patients treated with cetuximab. We investigated the association of these polymorphisms and
clinical outcome in a large cohort of mCRC patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin
(Nordic FLOX) +/- cetuximab in the NORDIC-VII study (NCT00145314).
Methods: 504 and 497 mCRC patients were evaluable for the FCGR2A and FCGR3A genotyping, respectively.
Genotyping was performed on TaqMan ABI HT 7900 (Applied Biosystems, Foster City, CA, USA) with pre-designed
SNP genotyping assays for FCGR2A (rs1801274) and FCGR3A (rs396991).
Results: The response rate for patients with the FCGR2A R/R genotype was significantly increased when cetuximab
was added to Nordic FLOX (31% versus 53%, interaction P = 0.03), but was not significantly different compared to
the response rate of patients with the FCGR2A H/H or H/R genotypes given the same treatment. A larger increase in
response rate with the addition of cetuximab to Nordic FLOX in patients with KRAS mutated tumors and the
FCGR2A R/R genotype was observed (19% versus 50%, interaction P = 0.04). None of the FCGR3A polymorphisms
were associated with altered response when cetuximab was added to Nordic FLOX (interaction P = 0.63). Neither of
the FCGR polymorphisms showed any significant associations with progression-free survival or overall survival.
Conclusion: Patients with KRAS mutated tumors and the FCGR2A R/R polymorphism responded poorly when treated
with chemotherapy only, and experienced the most benefit of the addition of cetuximab in terms of response rate.
Keywords: Colorectal cancer, FCGR2A, FCGR3A, Polymorphism, CetuximabBackground
The prognosis for patients with metastatic colorectal
cancer (mCRC) remains poor even though the addition
of newer chemotherapeutic agents and targeted drugs
has increased the median survival from 12 months
with fluorouracil monotherapy to roughly 2 years [1].* Correspondence: Elin.Kure@rr-research.no
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unless otherwise stated.Cetuximab, a monoclonal antibody targeting the epider-
mal growth factor receptor (EGFR), has shown efficacy in
combination with chemotherapy or given as monotherapy
in a small fraction of mCRC patients [2]. Clinical benefit
seems to be restricted to patients with KRAS wild-type
tumors [3,4]. In the recent NORDIC-VII study, however,
we did not find an improved outcome of adding cetuximab
to first-line oxaliplatin-based chemotherapy in patients with
KRAS wild-type tumors [5]. Similar results were found
by the COIN trial and the recent EPOC study [6,7]. Thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plore predictive markers independent of KRAS status to
avoid unnecessary drug toxicity and reduce treatment
cost.
Cetuximab may exert its antitumor effect through
multiple mechanisms. One mechanism of its antitumor
effects is through antibody-dependent cellular cytotoxicity
(ADCC) [8]. ADCC is induced through the interaction of
the Fc region of the monoclonal antibody with the Fc
gamma receptor (FCGR), surface receptors for immuno-
globulin G (IgG), located on immune effector cells such as
natural killer lymphocytes and macrophages [9]. Polymor-
phisms have been demonstrated on genes encoding for
the receptors FCGR2A and FCGR3A, affecting their affinity
to human IgG: a histidine(H)/arginine(R) polymorphism at
position 131 for FCGR2A and a valine (V)/phenylalanine
(F) polymorphism at position 158 for FCGR3A [10]. The
polymorphisms have been reported to be associated with
clinical outcome to the monoclonal antibodies rituximab
[11,12] and trastuzumab [13,14] in the treatment of
lymphoma and breast cancer, respectively.
Previous studies exploring these polymorphisms in rela-
tion to cetuximab effect in mCRC have shown conflicting
results and have been dominated by low-powered studies.
The aim of the present study was to investigate the as-
sociation between these polymorphisms and the effect
of cetuximab treatment in a large mCRC patient cohort;
the NORDIC-VII cohort. We examined the FCGR2A and
FCGR3A polymorphisms as potential markers to predict
cetuximab effect in 504 and 497 evaluable mCRC pa-
tients, respectively, treated with conventional chemo-
therapy (Nordic FLOX) with and without the addition
of cetuximab.
Methods
NORDIC VII
In the NORDIC VII trial (NCT00145314, registered
September 2, 2005), a total of 571 patients with mCRC
were randomized to receive first-line standard Nordic
FLOX (bolus 5-fluorouracil/folinic acid and oxalipla-
tin) (arm A), cetuximab and Nordic FLOX (arm B), or
cetuximab combined with intermittent Nordic FLOX
(arm C). Primary endpoint was progression-free survival
(PFS). Overall survival (OS) and response rate were
secondary endpoints. DNA from primary tumors was
screened for the presence of seven KRAS mutations
(codons 12 (G12D, G12A, G12V, G12S, G12C, G12R)
and 13 (G13D)) and one BRAF (BRAF V600E) mutation
as previously described [5]. KRAS and BRAF mutation
analyses were obtained in 498 (88%) and 457 patients
(81%), respectively. KRAS mutations in codons 12 and 13
were found in 39% of the tumors. BRAF mutations
(V600E) were present in 12% of the tumors. The muta-
tional frequencies of the 195 KRAS mutations in theNORDIC VII cohort were; G12A (9.7%), G12R (1.5%),
G12D (35.4%), G12C (9.7%), G12S (6.2%), G12V (15.4%),
and G13D (22.1%). Cetuximab did not add significant
benefit to Nordic FLOX and KRAS mutation was not pre-
dictive for cetuximab effect. DNA from a total of 504 and
497 of the 566 patients in the intention to treat population
was evaluable for the FCGR2A and FCGR3A genotyping,
respectively. There were 172 patients in arm A and 332
patients in arms B and C evaluable for response and sur-
vival analyses for the FCGR2A polymorphism. There were
169 patients in arm A and 328 patients in arms B and C
evaluable for response and survival analyses for the
FCGR3A polymorphism. KRAS status was available from
442 and 437 patients with FCGR2A and FCGR3A status,
respectively. BRAF status was available from 410 and 405
patients with FCGR2A and FCGR3A status, respectively.
Response status was evaluated according to the RECIST
version 1.0 criteria and was assigned to patients with
complete or partial remission with changes in tumor mea-
surements confirmed by repeat studies performed no less
than 4 weeks after the criteria for response were first met
(minimal interval of 8 weeks – 4 cycles) [15]. The study
was approved by national ethics committees and govern-
mental authorities in each country and was conducted in
accordance with the Declaration of Helsinki. All patients
provided written informed consent.
Primary tumors in the NORDIC VII study were screened
for KRAS exon 2 (codons 12 and 13) mutations. However,
recent studies have demonstrated that wild-type RAS
should be defined by the absence of KRAS exons 2, 3,
and 4 mutations and the absence of NRAS exons 2, 3, and
4 mutations [16-18]. A follow-up study of the NORDIC VII
cohort will include these additional mutational analyses.
FCGR2A-H131R and FCGR3A-V158F genotyping
Genotyping was performed on a TaqMan ABI HT 7900
(Applied Biosystems, Foster City, CA, USA) with pre-
designed SNP genotyping assays for FCGR2A c.535A >G
(rs1801274; resulting in amino-acid change of histidine
to arginine at position 131) and FCGR3A c.818A > C
(rs396991; resulting in amino-acid change of valine to
phenylalanine at position 158), according to the manufac-
turer’s protocol. Negative controls (water) were included.
Statistical analyses
The χ2-test and one-way ANOVA were used to compare
categorical and continuous variables between groups, as
appropriate, respectively. Homoscedasticity was ascertained
and the non-parametric Kruskal-Wallis test was applied as
a sensitivity analysis. For the prognostic analyses all three
arms (arms A, B and C) were analyzed together. For the
predictive analyses of cetuximab effect by FCGR2A or
FCGR3A genotype, arm A was compared to arms B and C
combined. The associations between the FCGR2A and
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binary logistic regression. PFS and OS times were esti-
mated using the Kaplan-Meier method. The associations
of the FCGR2A and FCGR3A genotypes and PFS and OS
were analyzed by Cox’s proportional hazards model. The
assumption of proportional hazards was checked by in-
spection of log minus log plots. The potential value of
FCGR2A and FCGR3A as predictive markers of cetuxi-
mab effect was analyzed by including an interaction
term in the models. The distributions of the FCGR2A
and FCGR3A genotypes in the NORDIC-VII study were
tested for Hardy-Weinberg equilibrium [19]. P < 0.05
was considered statistically significant. All statistical
analyses were performed using Statistical Package for
Social Sciences, version 18.0 (SPSS Chicago, IL).
Results
Patient characteristics
Table 1 depicts the frequencies of the analyzed FCGR2A
and FCGR3A genotypes, which were in Hardy-Weinberg
equilibrium (P = 0.41 and 0.54, respectively). There were
no significant associations of any of the FCGR2A or
FCGR3A genotypes with clinicopathological characteris-
tics (age, sex, location of primary tumor, metastatic sites,
KRAS, or BRAF mutation status) or treatment, Table 2.
Response rate and survival
There was no significant difference in response rates for
the different FCGR2A and FCGR3A genotypes when
analyzing all the three treatment arms together (P = 0.89
and 0.82, respectively), Table 2. There was also no signifi-
cant association of any of the FCGR2A or FCGR3A geno-
types with PFS (Log rank P = 0.45 and 0.76, respectively)
or OS (Log rank P = 0.42 and 0.77, respectively), Table 2.
Predictive analyses for benefit of cetuximab treatment
The FCGR2A R/R genotype was associated with increased
response rate when cetuximab was added to Nordic FLOX
regardless of mutational status (31% in arm A versus 53%
in arms B + C, interaction P = 0.03), but was not signifi-
cantly different compared to the response rate of patientsTable 1 FCGR2A and FCGR3A genotypes in the study populat
Actual frequency
of genotypes (n)
Expected frequen
of genotypes (n)
FCGR2A
H/H 114 118.61
H/R 261 251.78
R/R 129 133.61
FCGR3A
F/F 241 238.10
F/V 206 211.8
V/V 50 47.10with the FCGR2A H/H or H/R genotypes given the same
treatment, Table 3 and Figure 1. There was no significant
difference in response rates in the FCGR2A subgroups in
patients with KRAS wild-type tumors after the addition of
cetuximab, Table 4 and Figure 2. A significant increase in
response rate with the addition of cetuximab to Nordic
FLOX in patients with KRAS mutated tumors and the
FCGR2A R/R genotype was observed (19% versus 50%,
interaction P = 0.04), Table 4 and Figure 3. None of the
FCGR3A polymorphisms were associated with altered
response when cetuximab was added to Nordic FLOX
(interaction P = 0.63), Table 3. The FCGR3A genotypes
were not associated with response to cetuximab when
stratified for BRAF or KRAS mutational status, Table 5.
Median PFS and OS were similar in arms B + C
as compared to arm A for the FCGR2A (Log rank
P = 0.35 and 0.85) and the FCGR3A (Log rank P = 0.41
and 0.78) genotypes, Table 3. The median PFS and OS
were also similar in arms B + C compared to arm A
for both the FCGR2A and FCGR3A genotypes when
stratified for BRAF or KRAS mutational status, Tables 4
and 5.Discussion
We studied the FCGR2A and the FCGR3A polymorphisms
in a large cohort of mCRC patients treated with conven-
tional chemotherapy with and without cetuximab in an
effort to explore potential associations between these
polymorphisms and cetuximab effect. Our results show
that the addition of cetuximab to Nordic FLOX lead to
a statistically significant increase in response rate in
patients with the FCGR2A R/R genotype. Subgroup
analysis of patients with KRAS mutated tumors and the
FCGR2A R/R genotype showed an even larger increase in
response after the addition of cetuximab.
Previous studies exploring the relation between the
FCGR polymorphisms and cetuximab efficacy in mCRC
have demonstrated conflicting or negative results and
have been mostly low-powered studies with small sam-
ple sizes. Our study is one of the largest reported so farion
cy Hardy-Weinberg equilibrium
X2 (1 degree of freedom)
P-value
0.68 0.41
0.37 0.54
Table 2 Patient characteristics and treatment outcome by FCGR2A and FCGR3A genotypes
FCGR2A FCGR3A
H/H H/R R/R P-value F/F F/V V/V P-value
Number of patients (%) 114 (22.6%) 261 (51.8%) 129 (25.6%) 241 (48.5%) 206 (41.4%) 50 (10.1%)
Age, median (range) 61 (27–74) 62 (24–75) 62 (30–75) 0.99* 62 (24–75) 61 (29–75) 61 (35–75) 0.47*
Sex, female/male 49/65 102/159 57/72 0.58† 93/148 94/112 20/30 0.32†
Location, colon/rectum 71/43 145/116 78/51 0.41† 147/94 121/85 23/27 0.15†
Metastatic sites, 1/>1 32/82 63/198 39/90 0.41† 62/179 51/155 20/30 0.08†
KRAS, wt/mutated 62/38 150/82 61/49 0.26† 126/87 111/67 31/15 0.54†
BRAF, wt/mutated 80/11 192/26 91/10 0.88† 182/18 141/21 36/7 0.28†
Treatment, FLOX/FLOX + cetuximab 33/81 90/171 49/80 0.34† 79/162 75/131 15/35 0.58†
Response; response/no-response 54/60 121/140 57/72 0.89† 109/132 93/113 25/25 0.82†
PFS (months), median 8.3 7.9 7.6 0.45‡ 7.9 7.6 8.4 0.76‡
OS (months), median 21.9 19.8 18.2 0.42‡ 19.9 20.5 19.7 0.77‡
*One-way ANOVA (The Kruskal-Wallis test produced similar p-values),†Chi-square test ‡Log-rank test.
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trol group where patients did not receive cetuximab.
Even though their results were not statistically signifi-
cant, the FCGR2A R/R genotype had a better response rate
compared to the H/R or the H/H genotypes in KRAS wild-
type patients treated with cetuximab or panitumumab as
monotherapy or in combination with chemotherapy in a
study of 104 refractory mCRC patients [20]. Furthermore,
a pooled analysis including 217 mCRC patients treated
with cetuximab alone or with chemotherapy showed that
patients with the FCGR2A R/R or H/R alleles had a statisti-
cally significant longer median PFS than the H/H genotype
[21]. Moreover, a study by Negri et al., where most of the
86 mCRC patients enrolled in the study were treated with
cetuximab and irinotecan, demonstrated a higher OS
in mCRC patients with the FCGR2A R/R polymorphism
[22]. However, the authors concluded that the polymorph-
ism was not predictive of cetuximab effect since no
relation to response or time to progression (TTP) was
demonstrated [22].Table 3 Treatment outcome by FCGR2A and FCGR3A genotyp
FLOX
FCGR2A H/H H/R R/R
Number of patients N = 33 N = 90 N = 49
Response (%) 58% (19/33) 41% (37/90) 31% (15/49)
PFS, median (months) 8.4 7.9 7.5
OS, median (months) 28.0 20.5 19.8
FCGR3A F/F F/V V/V
Number of patients N = 79 N = 75 N = 15
Response (%) 38% (30/79) 41% (31/75) 53% (8/15)
PFS, median (months) 7.6 8.4 7.8
OS, median (months) 20.4 20.5 19.7
*Logistic regression, †Cox proportional hazard model.Conversely, a study which included 69 mCRC patients
reported the FCGR2A H/H alone or in combination
with FCGR3A V/V to be associated with longer PFS in
irinotecan-refractory mCRC patients with KRAS wild-
type and KRAS mutated tumors treated with cetuximab
plus irinotecan [23]. The difference remained significant
for KRAS mutated patients. Similar results were demon-
strated by Rodriguez et al., who reported that patients
with any FCGR2A H and/or FCGR3A V allele were more
likely to show a response or have stable disease [24].
Rodriguez et al. explored if the FCGR genotypes would
predict which patients with a KRAS, or other down-
stream mutations, would respond to cetuximab. They
included 47 mCRC patients treated with cetuximab and
standard chemotherapy with a KRAS, BRAF, NRAS, or
PI3K mutation in the FCGR genotype analysis. Two
other studies including 52 and 49 mCRC patients,
respectively, reported only the FCGR3A V/V genotype
to be associated with a better response to cetuximab
[25,26].es, and therapy received
FLOX + cetuximab Interaction P-value
H/H H/R R/R
N = 81 N = 171 N = 80
43% (35/81) 49% (84/171) 53% (42/80) 0.03*
8.3 7.8 7.6 0.35†
21.4 19.5 17.3 0.85†
F/F F/V V/V
N = 162 N = 131 N = 35
49% (79/162) 47% (62/131) 49% (17/35) 0.63*
8.1 7.4 9.3 0.41†
19.7 21.1 20.1 0.78†
Figure 1 FCGR2A response rates in the whole study population. The FCGR2A R/R genotype was associated with increased response rate
when cetuximab was added to Nordic FLOX (31% in arm A vs 53% in arms B + C, interaction P = 0.03).
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122 mCRC patients, respectively, have reported the
FCGR3A F/F allele to be associated with a better clinical
outcome [27-29]. The former study demonstrated that
patients enrolled in the BOND-2 study with the FCGR3A
F/F allele had a significantly better response to cetuximab
in combination with bevacizumab in irinotecan-refractory
mCRC patients [27]. There was shorter survival in pa-
tients with the FCGR3A V/V genotype as compared to
V/F or F/F in the study of 58 mCRC patients who re-
ceived irinotecan in combination with cetuximab [28].Table 4 Treatment outcome by FCGR2A genotype, KRAS or BR
FLOX
H/H H/R R/R
KRAS wild-typ
Number of patients N = 16 N = 52 N = 20
Response 63% (10/16) 42% (22/52) 45% (9/20)
PFS 8.4 8.9 9.0
OS 31.6 23.6 19.0
KRAS mutated
Number of patients N = 10 N = 25 N = 21
Response 60% (6/10) 52% (13/25) 19% (4/21)
PFS 8.1 8.3 7.1
OS 17.2 20.4 24.3
BRAF wild-typ
Number of patients N = 22 N = 62 N = 34
Response 64% (14/22) 48% (30/62) 35% (12/34)
PFS 9.3 8.9 7.7
OS 31.6 23.8 21.5
BRAF mutate
Number of patients N =3 N = 10 N = 4
Response 33% (1/3) 20% (2/10) 0% (0/4)
PFS 4.3 5.1 3.8
OS 9.2 9.4 5.6
*Logistic regression, †Cox proportional hazard model.This was shown in the whole study population and in a
subgroup analysis of patients with KRAS wild-type
tumors. Moreover, the latter study by Pander et al., found
mCRC patients in the CAIRO2 study with the FCGR3A
F/F allele to be associated with longer PFS in KRAS wild-
type patients treated with cetuximab as first-line treatment
in combination with capecitabine, oxaliplatin and beva-
cizumab [29]. A smaller study including only 39 mCRC
patients reported the FCGR2A, any H allele, and FCGR3A,
any F allele, to be associated with longer PFS in mCRC
patients who were treated with single-agent cetuximabAF mutational status, and therapy received
FLOX + cetuximab
H/H H/R R/R Interaction P-value
e (N = 273)
N = 46 N = 98 N = 41
46% (21/46) 51% (50/98) 56% (23/41) 0.27*
7.7 7.7 8.0 0.23†
21.4 20.7 18.9 0.23†
(N = 169)
N = 28 N = 57 N = 28
36% (10/28) 46% (26/57) 50% (14/28) 0.04*
7.7 8.1 6.7 0.90†
21.1 20.0 16.8 0.34†
e (N = 363)
N = 58 N = 130 N = 57
47% (27/58) 52% (68/130) 54% (31/57) 0.10*
8.5 8.1 8.0 0.47†
21.9 21.5 17.6 0.93†
d (N = 47)
N = 8 N = 16 N = 6
13% (1/8) 25% (4/16) 33% (2/6) 0.72*
3.8 4.6 5.8 0.36†
8.9 8.1 11.3 0.73†
Figure 2 FCGR2A response rates in patients with KRAS wild-type tumors. There was no significant difference in response rates when
cetuximab was added to Nordic FLOX in the different FCGR2A subgroups (interaction P = 0.27).
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the sample size was increased to a total of 130 patients
[31]. In addition to the study by Lurje et al., four other
studies with a higher number of patients have reported lack
of significant associations of the FCGR2A or FCGR3A poly-
morphisms and cetuximab efficacy in mCRC [20,32-34].
Our study show that patients with KRAS mutated tu-
mors and the FCGR2A R/R genotype responded poorly
when treated with chemotherapy only and experienced
the most benefit of the addition of cetuximab in terms
of response rate. In line with this, Correale et al. demon-
strated that activating KRAS mutations in colon cancer
cell lines may correlate with a higher susceptibility to
cetuximab-mediated ADCC [35]. Another study by
Schlaeth et al. found that KRAS mutated tumor cells could
be effectively killed by ADCC, indicating that mutated
KRAS is not enough to confer resistance to antibody-
mediated cell killing [36].
The conflicting findings in the different studies dem-
onstrate the importance of sample size when studying
the effect of polymorphisms in relation to clinical out-
come. Moreover, the heterogeneity among the differentFigure 3 FCGR2A response rates in patients with KRAS mutated tumo
rate when cetuximab was added to Nordic FLOX (19% in arm A vs 50% instudies, such as study design, ethnicity, previous and
concomitant treatment, and the distribution of genotypes
may also partly explain the discordance. Furthermore, the
retrospective nature of most of the studies and the use of
different endpoints may also contribute to the conflicting
results. Additionally, Clynes et al. found the IgG1 anti-
bodies trastuzumab and rituximab to engage in both
activatory (FCGR3A) and inhibitory receptors (FCGR2B)
and the in vivo activity of the antibodies may be more
predictable by the ratio of FCGR3A to FCGR2B (A/I
ratio) [37] which has not been investigated in the
reported studies. Furthermore, all the studies have only
tested two polymorphisms in only two genes involved
in the ADCC mechanism. Also, other effector mecha-
nisms of cetuximab may play a more important role,
such as complement-dependent cytotoxicity, apoptosis
and phagocytosis.
More importantly, ADCC may not play a correspond-
ingly important role in metastatic cancer patients as dem-
onstrated in in vitro models. ADCC has been shown to be
markedly impaired with natural killer cell dysfunction in
cancer patients with metastatic disease [38]. Moreover, thers. The FCGR2A R/R genotype was associated with increased response
arms B + C, interaction P = 0.04).
Table 5 Treatment outcome by FCGR3A genotype, KRAS or BRAF mutational status, and therapy received
FLOX FLOX + cetuximab
F/F F/V V/V F/F F/V V/V Interaction P-value
KRAS wild-type (N =268)
Number of patients N = 39 N = 38 N = 9 N = 87 N = 73 N = 22
Response 44% (17/39) 45% (17/38) 56% (5/9) 48% (42/87) 51% (37/73) 55% (12/22) 0.95*
PFS 7.8 9.0 8.4 8.0 7.3 11.8 0.72†
OS 23.1 20.5 25.2 17.6 25.9 20.5 0.97†
KRAS mutated (N =169)
Number of patients N = 28 N = 21 N = 6 N = 59 N = 46 N = 9
Response 36% (10/28) 48% (10/21) 50% (3/6) 51% (30/59) 39% (18/46) 33% (3/9) 0.28*
PFS 7.8 8.1 4.0 8.3 7.0 6.9 0.19†
OS 18.5 24.3 17.1 21.3 17.7 16.4 0.63†
BRAF wild-type (N = 359)
Number of patients N = 56 N = 47 N = 12 N = 126 N = 94 N = 24
Response 45% (25/56) 49% (23/47) 50% (6/12) 52% (65/126) 48% (45/94) 63% (15/24) 0.71*
PFS 7.9 9.1 7.8 8.3 7.6 11.5 0.58†
OS 23.8 23.6 19.7 20.6 22.9 20.5 0.93†
BRAF mutated (N = 46)
Number of patients N = 8 N = 7 N = 2 N = 10 N = 14 N = 5
Response 13% (1/8) 14% (1/7) 50% (1/2) 20% (2/10) 29% (4/14) 0% (0/5) 0.99*
PFS 5.9 4.3 4.4 4.2 5.4 4.6 0.87†
OS 9.5 9.4 5.2 10.8 8.9 10.3 0.66†
*Logistic regression, †Cox proportional hazard model.
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the myeloablative effects of chemotherapy which may
impair ADCC [39].
Primary tumors in the NORDIC VII study were screened
for KRAS exon 2 (codons 12 and 13) mutations. Recent
studies have though demonstrated that the selection of pa-
tients for anti-EGFR therapy may improve by considering
RAS mutations other than KRAS exon 2 mutations (NRAS
exons 2, 3, and 4 and KRAS exons 3 and 4) [16-18]. It is
expected to find up to 17% mutations in the KRAS exon 2
wild-type population in the NORDIC VII cohort. We do
not expect that the contribution of the additional muta-
tions will considerably alter the outcome of the FCGR
polymorphisms. Lack of this data is however a limitation
of the present study.
Conclusions
Patients with KRAS mutated tumors and the FCGR2A
R/R genotype responded poorly when treated with
chemotherapy only and experienced the most benefit
of the addition of cetuximab in terms of response rate.
The response rate for the FCGR2A R/R genotype was
however not significantly larger than in the other two
FCGR2A genotypes (H/R and H/H) in patients treated
with Nordic FLOX and cetuximab. Moreover, there
was no significant association between any of the
FCGR2A genotypes and PFS or OS and the implicationof this finding thus remains of uncertain clinical rele-
vance. Many potential associations have been studied,
and due to multiplicity a small number of low p-values
would be expected to occur by chance even if no true
associations exist. Furthermore, we found no significant as-
sociation between any of the FCGR3A genotypes and re-
sponse, PFS, or OS. Although our study has a larger sample
size than most previously published studies, the sample size
in the FCGR subgroups is still too low to obtain sufficient
power and larger statistically powered studies to evaluate
the significance of the FCGR polymorphisms are needed.
Furthermore, the NORDIC VII cohort has limitations for
studies of biomarkers predictive of cetuximab effect, as
cetuximab did not add significant benefit to the Nordic
FLOX regimen. In conclusion, we consider the FCGR2A
and FCGR3A polymorphisms not to be currently useful
predictive markers of cetuximab efficacy in mCRC.
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